Plk1、Chk1/2在原发性肝癌组织及HepG2细胞中的表达研究

摘要

Objective:To investigate the expression of Plk1 ( Polo-like kinase 1 ) and Chk1/2 ( Checkpoint kinase 1/2 ) in primary hepatic carcinoma tissue and HepG2 cell. Methods: Using immunohistochemistry chemical method detected expression of Plk1,Chk1/2 protein in 40 cases of primary hepatic carcinoma tissue and 16 cases of non-tumor tissue of liver. Western blot was applied to detect the expression of Plk1 and Chk1/2 protein in HepG2 cells, and gray value was measured by using the quantitative analysis. Results:The positive rate of Plk1,Chk1/2 protein expression in primary hepatic carcinoma was 57. 5%,75. 0% and 22. 5%respectively,compared with positive rate in the liver of non-tumor tissue were 0%,25. 0% and 56. 3%. The expression of Plk1 and Chk1 protein in primary hepatic carcinoma tissue is higher than that in non-tumor tissue of liver,and the difference was statistically sig-nificant( P<0. 05 ) . The expression of Chk2 in primary hepatic carcinoma was lower than that in hepatic non-tumor tissue, and the difference was statistically significant(P<0. 05) too. The expression of Plk1,Chk1/2 protein were detected in HepG2 cells and the relative expression rate of Plk1,Chk1/2 protein were 0.39±0.0226,0.08±0.0249 and 0.01±0.0066 respectively,the difference between them was statistically significant. The expression degree was Plk1>Chk1>Chk2. Conclusion: Plk1,Chk1 protein in primary hepatic carcinoma was up-regulated,while Chk2 protein was down-regulated in these tissues. The expression degree was Plk1> Chk1>Chk2. There were relatively selective expression in primary hepatic carcinoma tissue of Plk1,Chk1 protein,then Plk1 and Chk1 might be ideal targets for therapy of primary hepatic carcinoma.%目的：：研究保罗样激酶1(Polo-like kinase1,Plk1)、细胞周期检测点激酶1、2(Checkpoint kinase 1/2,Chk1/2)在原发性肝癌组织与人肝癌细胞HepG2中的表达情况。方法：使用免疫组织化学Envision法检测40例原发性肝癌组织及16例肝非肿瘤组织中Plk1、Chk1/2蛋白的表达。提取培养后的HepG2细胞蛋白。利用蛋白免疫印记( Western blot)技术定性分析Plk1、Chk1/2蛋白在HepG2细胞中的表达情况,并测定灰度值进行定量分析。结果：原发性肝癌组织中Plk1、Chk1蛋白的阳性表达率分别是57．5%、75%,高于它们在肝非瘤组织中的表达率0%、25．0%(P<0．05)。 Chk2在原发性肝癌组织中的表达阳性率22．5%,低于肝非肿瘤组织中的表达率56．3%(P<0．05)。 Plk1、Chk1/2蛋白在HepG2细胞中均有表达。其相对表达量分别是：0．39±0．0226、0．08±0．0249、0．01±0．0066,三者之间的差异均有统计学意义,其表达的顺序依次为Plk1>Chk1>Chk2。结论：Plk1、Chk1蛋白在原发性肝癌组织中表达上调,而Chk2蛋白在原发性肝癌组织中表达下调。 Plk1、Chk1/2基因作为细胞周期调控中的重要激酶在HepG2细胞中均有表达,其表达顺序为Plk1>Chk1>Chk2。Plk1、Chk1具有相对意义的肿瘤选择性表达,可能成为肝癌生物治疗中新的治疗靶点。